0001603756-20-000070.txt : 20200806 0001603756-20-000070.hdr.sgml : 20200806 20200806160510 ACCESSION NUMBER: 0001603756-20-000070 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 15 CONFORMED PERIOD OF REPORT: 20200806 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20200806 DATE AS OF CHANGE: 20200806 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Axonics Modulation Technologies, Inc. CENTRAL INDEX KEY: 0001603756 STANDARD INDUSTRIAL CLASSIFICATION: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841] IRS NUMBER: 454744083 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-38721 FILM NUMBER: 201081534 BUSINESS ADDRESS: STREET 1: 26 TECHNOLOGY DRIVE CITY: IRVINE STATE: CA ZIP: 92618 BUSINESS PHONE: 949-396-6322 MAIL ADDRESS: STREET 1: 26 TECHNOLOGY DRIVE CITY: IRVINE STATE: CA ZIP: 92618 8-K 1 axnx-063020x8kdocument.htm 8-K Document
false0001603756 0001603756 2020-08-06 2020-08-06


 
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
  _________________________________________________________________
FORM 8-K
 _________________________________________________________________
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of The
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2020
_________________________________________________________________
Axonics Modulation Technologies, Inc.
(Exact name of registrant as specified in its charter)
_________________________________________________________________
Delaware
 
001-38721
 
45-4744083
(State or other jurisdiction
of incorporation)
 
(Commission File Number)
 
(I.R.S. Employer
Identification No.)
26 Technology Drive
Irvine, California 92618
(Address of principal executive offices) (Zip Code)
(949) 396-6322
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
  _________________________________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
☐
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
☐
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
☐
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
☐
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
 
 
Emerging growth company
☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ☒
Securities registered pursuant to Section 12(b) of the Exchange Act:
Title of class
Trading symbol
Name of exchange on which registered
Common stock, par value $0.0001 per share
AXNX
Nasdaq Global Select Market
 




Item 2.02.    Results of Operations and Financial Condition.
On August 6, 2020, Axonics Modulation Technologies, Inc. (the Company) issued a press release announcing its financial results for the quarter ended June 30, 2020. The full text of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
The information in this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section, nor shall it be deemed to be incorporated by reference into any filing of the Company under the Securities Act of 1933, as amended, except as expressly set forth by specific reference in such filing.
Item 9.01.    Financial Statements and Exhibits.
(d) Exhibits.
Exhibit No.
 
Description
99.1
 
104
 
Cover Page Interactive Date File - the cover page XBRL tags are embedded within the Inline XBRL document.




SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
 
 
 
 
 
 
 
AXONICS MODULATION TECHNOLOGIES, INC.
 
 
 
Date: August 6, 2020
 
By:
 
/s/ Raymond W. Cohen
 
 
 
 
Raymond W. Cohen
 
 
 
 
Chief Executive Officer


 EX-99.1 2 axnx-063020xex991.htm EXHIBIT 99.1 Exhibit
Exhibit 99.1
Axonics® Reports Second Quarter 2020 Results

IRVINE, CA – August 6, 2020 – Axonics Modulation Technologies, Inc. (NASDAQ: AXNX), a medical technology company that has developed and is commercializing novel implantable sacral neuromodulation (SNM) devices for the treatment of urinary and bowel dysfunction, today reported financial results for the second quarter 2020 and provided an update on operational initiatives.
Financial Highlights
•
Net revenue was $15.2 million in the second quarter ended June 30, 2020 as compared to net revenue of $1.5 million for the same period of the prior year. Net revenue for the first half of 2020 was $41.5 million as compared to $2.6 million for the first half of 2019.
◦
As previously disclosed, new order flow was de minimis in April due to COVID-19 related restrictions on elective procedures and began a gradual recovery in early May as restrictions were lifted in certain states. New orders in June continued to improve. Average weekly new order flow in June was approximately 70% of the weekly average achieved in the first quarter of 2020 prior to the COVID-19 related postponement of elective procedures in mid-March.
•
Axonics raised $140 million of net proceeds in a public equity offering in May 2020. As of June 30, 2020, cash and cash equivalents were $288 million.
Business and Clinical Highlights
•
Through the end of July 2020, over 540 unique accounts (hospitals and ambulatory surgery centers) in the U.S. have implanted the Axonics r-SNM System® in patients on an outpatient basis since the product launched in November 2019.
•
Since the U.S. launch, over 135 corporate agreements have been signed with national and regional integrated delivery networks (IDN) as well as large urology groups and ambulatory surgery centers. Included in this group are agreements with 12 of the largest 17 national IDNs in the U.S.
•
Axonics recently reported 2-year topline clinical results from its ARTISAN-SNM pivotal study. At 2-years post-implant, 88% of all patients were therapy responders, consistent with the 89% therapy responder rate reported at 1-year. The 2-year results demonstrate that patients continue to experience clinically meaningful and statistically significant improvements in urinary urgency incontinence symptoms and quality of life. Eighty percent of patients achieved >75% reduction in symptoms, with 37% being completely dry. There were no serious or unanticipated device related events.
Regulatory Approvals
•
In April 2020, the U.S. Food & Drug Administration (FDA) approved a next generation rechargeable implantable neurostimulator (INS) for the Axonics r-SNM System under a premarket approval (PMA) supplement. The new INS extends the recharge interval for patients to only once a month for about one hour and for some patients, only once every two months. The next generation Axonics INS is shipping to U.S. customers this week.
•
In June 2020, the FDA approved a new wireless patient remote control with SmartMRI™ technology for the Axonics r-SNM System under a PMA supplement. The new remote control simplifies the process by which patients can receive a full-body MRI. An MRI technician can perform a simple check using a patient’s remote control immediately prior to an MRI, avoiding the need for the patient to visit their implanting physician’s office or involving personnel from Axonics.


•
In July 2020, the FDA approved 3T full-body MRI conditional labeling for the Axonics r-SNM System under a PMA supplement. With this incremental approval, the Axonics device is MRI compatible for both 1.5T and 3T full-body scans.
Raymond W. Cohen, Axonics CEO, commented, “Axonics was exceptionally productive in the second quarter, having built a significant quantity of finished goods inventory, signed numerous IDN agreements, added over 110 new accounts, and gained several FDA approvals. Despite COVID-19 flare-ups in certain geographies, based on the number of accounts that have switched to Axonics and the trajectory of new order flow in July, we are confident that Axonics is well positioned for continued strong growth in the second half of 2020.”
Mr. Cohen continued, “The responder rate from the ARTISAN-SNM pivotal study is the highest success rate ever reported in SNM clinical literature and will soon appear in print in a peer-reviewed journal. More importantly, these results are being replicated by hundreds of physicians in commercial cases all over the U.S. These clinical results, when combined with other key features of our SNM System such as a 15+ year life, recharging only once per month for an hour, full-body MRI compatibility, and ease of use create significant and distinct advantages over the competitive offering. The overwhelmingly positive feedback from physicians, their staff and patients on their experience with Axonics supports our conviction that SNM is poised for significant market expansion in the years ahead.”
Second Quarter 2020 Financial Results
•
Net revenue was $15.2 million in the second quarter 2020, as compared to net revenue of $1.5 million for the same period of the prior year. Net revenue from the U.S. accounted for $14.6 million, with select European markets and Canada accounting for the balance of second quarter 2020 revenue.
•
Gross margin was 44.4% in the second quarter 2020, as compared to 48.1% for the same period of the prior year. The decrease in gross margin was primarily due to lower overhead absorption related to the COVID-19 pandemic in second quarter 2020. Management anticipates gross margin will return to the low to mid sixty percent range in the second half of 2020 and anticipates the low to mid seventy percent range over the longer-term.
•
Operating expenses were $26.2 million in the second quarter 2020, as compared to $20.0 million for the same period of the prior year. This increase was primarily due to higher personnel costs for the U.S. commercial team and in other parts of the organization.
•
Net loss was $19.8 million in the second quarter 2020, as compared to a net loss of $19.1 million for the same period of the prior year. Cash used in operating activities in the second quarter 2020 was $13.0 million.
•
As of June 30, 2020, cash and cash equivalents were $288 million.
Webcast and Conference Call
Axonics will host a conference call today, August 6, 2020, at 4:30 p.m. Eastern Time, to discuss financial results and recent business developments.
Interested parties may access the live teleconference by dialing 866-687-5771 (U.S.) or 409-217-8725 (International) and using conference ID 2397731.
A live webcast of the conference call may be accessed by visiting the Events & Presentations section of the Axonics investor relations website at ir.axonics.com. A replay of the webcast will be available shortly after the conclusion of the call and will be archived on the Axonics website for 90 days.
About Axonics Modulation Technologies, Inc.
Axonics, based in Irvine, Calif., has developed and is commercializing novel implantable SNM devices for patients with urinary and bowel dysfunction. These conditions are caused by a miscommunication between


the bladder and the brain and significantly impacts quality of life. Overactive bladder affects an estimated 87 million adults in the U.S. and Europe. Another estimated 40 million adults are reported to suffer from fecal incontinence/accidental bowel leakage. Axonics SNM therapy, which has been clinically proven to reduce symptoms and restore pelvic floor function, is now being offered at hundreds of medical centers across the U.S. and in dozens of select hospitals in Western Europe. Reimbursement coverage is well established in the U.S. and is a covered service in most European countries. The Axonics System is the first long-lived rechargeable SNM system approved for sale in the world, and the first to gain full-body MRI conditional labeling. For more information, visit www.axonics.com.
Forward-Looking Statements
Statements made in this press release that relate to future plans, events, prospects or performance are forward-looking statements as defined under the Private Securities Litigation Reform Act of 1995. Words such as “planned,” “expects,” “believes,” “anticipates,” “designed,” and similar words are intended to identify forward-looking statements. While these forward-looking statements are based on the current expectations and beliefs of management, such forward-looking statements are subject to a number of risks, uncertainties, assumptions and other factors that could cause actual results to differ materially from the expectations expressed in this press release, including the risks and uncertainties disclosed in Axonics filings with the Securities and Exchange Commission, all of which are available online at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Except as required by law, Axonics undertakes no obligation to update or revise any forward-looking statements to reflect new information, changed circumstances or unanticipated events.

Axonics contact:
Neil Bhalodkar
Investor Relations
949-336-5293
IR@axonics.com


Axonics Modulation Technologies, Inc.
Condensed Consolidated Balance Sheets
(in thousands, except share and per share data)
 
June 30,
 
December 31,
 
2020
 
2019
 
(unaudited)
 
 
ASSETS
 
 
 
Current assets
 
 
 
Cash and cash equivalents
$
287,679

 
$
171,082

Short-term investments
—

 
12,592

Accounts receivable, net of allowance for doubtful accounts of $589 and $75 at June 30, 2020 and December 31, 2019, respectively
14,115

 
7,879

Inventory, net
30,138

 
15,659

Prepaid expenses and other current assets
3,573

 
4,468

Total current assets
335,505

 
211,680

Property and equipment, net
5,562

 
3,047

Intangible asset, net
254

 
311

Other assets
7,415

 
4,784

Total assets
$
348,736

 
$
219,822

 
 
 
 
LIABILITIES AND STOCKHOLDERS’ EQUITY
 
 
 
Current liabilities
 
 
 
Accounts payable
$
10,728

 
$
5,882

Accrued liabilities
3,961

 
2,174

Accrued compensation and benefits
5,289

 
3,375

Operating lease liability, current portion
851

 
602

Debt, current portion
10,000

 
—

Total current liabilities
30,829

 
12,033

Operating lease liability, net of current portion
9,261

 
4,450

Debt, net of unamortized debt issuance costs, net of current portion
10,750

 
20,336

Total liabilities
50,840

 
36,819

Stockholders’ equity
 
 
 
Preferred stock, par value $0.0001 per share; 10,000,000 shares authorized, no shares issued and outstanding at June 30, 2020 and December 31, 2019
—

 
—

Common stock, par value $0.0001, 50,000,000 shares authorized at June 30, 2020 and December 31, 2019; 39,462,405 and 34,110,995 shares issued and outstanding at June 30, 2020 and December 31, 2019, respectively
4

 
3

Additional paid-in capital
512,588

 
363,012

Accumulated deficit
(213,983
)
 
(179,584
)
Accumulated other comprehensive loss
(713
)
 
(428
)
Total stockholders’ equity
297,896

 
183,003

Total liabilities and stockholders’ equity
$
348,736

 
$
219,822



Axonics Modulation Technologies, Inc.
Condensed Consolidated Statements of Comprehensive Loss
(in thousands, except share and per share data)
(unaudited)
 
Three Months Ended
June 30,
 
Six Months Ended
June 30,
 
2020
 
2019
 
2020
 
2019
Net revenue
$
15,213

 
$
1,488

 
$
41,509

 
$
2,565

Cost of goods sold
8,463

 
772

 
18,358

 
1,320

Gross profit
6,750

 
716

 
23,151

 
1,245

Operating Expenses
 
 
 
 
 
 
 
Research and development
6,398

 
4,874

 
13,282

 
9,093

General and administrative
5,537

 
4,362

 
13,190

 
8,377

Sales and marketing
14,220

 
10,750

 
30,789

 
16,664

Total operating expenses
26,155

 
19,986

 
57,261

 
34,134

Loss from operations
(19,405
)
 
(19,270
)
 
(34,110
)
 
(32,889
)
Other Income (Expense)
 
 
 
 
 
 
 
Interest income
65

 
839

 
707

 
1,873

Interest and other expense
(443
)
 
(629
)
 
(995
)
 
(1,161
)
Other income (expense), net
(378
)
 
210

 
(288
)
 
712

Loss before income tax expense
(19,783
)
 
(19,060
)
 
(34,398
)
 
(32,177
)
Income tax expense
—

 
1

 
1

 
1

Net loss
(19,783
)
 
(19,061
)
 
(34,399
)
 
(32,178
)
Foreign currency translation adjustment
(108
)
 
(43
)
 
(285
)
 
(53
)
Comprehensive loss
$
(19,891
)
 
$
(19,104
)
 
$
(34,684
)
 
$
(32,231
)
 
 
 
 
 
 
 
 
Net loss per share, basic and diluted
$
(0.54
)
 
$
(0.68
)
 
$
(0.98
)
 
$
(1.15
)
Weighted-average shares used to compute basic and diluted net loss per share
36,440,846

 
27,945,393

 
35,040,180

 
27,887,121


 EX-101.SCH 3 axnx-20200806.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0001000 - Document - Cover Page link:presentationLink link:calculationLink link:definitionLink EX-101.CAL 4 axnx-20200806_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE DOCUMENT EX-101.DEF 5 axnx-20200806_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT EX-101.LAB 6 axnx-20200806_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre-commencement Tender Offer Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Title of 12(b) Security Title of 12(b) Security Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name EX-101.PRE 7 axnx-20200806_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 8 axnx-063020x8kdocument_htm.xml IDEA: XBRL DOCUMENT 0001603756 2020-08-06 2020-08-06 false 0001603756 8-K 2020-08-06 Axonics Modulation Technologies, Inc. DE 001-38721 45-4744083 26 Technology Drive Irvine CA 92618 949 396-6322 false false false false true true Common stock, par value $0.0001 per share AXNX NASDAQ XML 9 R1.htm IDEA: XBRL DOCUMENT v3.20.2
Cover Page
Aug. 06, 2020
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001603756
Document Type 8-K
Document Period End Date Aug. 06, 2020
Entity Registrant Name Axonics Modulation Technologies, Inc.
Entity Incorporation, State or Country Code DE
Entity File Number 001-38721
Entity Tax Identification Number 45-4744083
Entity Address, Address Line One 26 Technology Drive
Entity Address, City or Town Irvine
Entity Address, State or Province CA
Entity Address, Postal Zip Code 92618
City Area Code 949
Local Phone Number 396-6322
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company true
Entity Ex Transition Period true
Title of 12(b) Security Common stock, par value $0.0001 per share
Trading Symbol AXNX
Security Exchange Name NASDAQ
EXCEL 10 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 11 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 12 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.20.2 html 1 95 1 false 0 0 false 0 false false R1.htm 0001000 - Document - Cover Page Sheet http://axonicsmodulation.com/role/CoverPage Cover Page Cover 1 false false All Reports Book All Reports axnx-063020x8kdocument.htm axnx-063020xex991.htm axnx-20200806.xsd axnx-20200806_cal.xml axnx-20200806_def.xml axnx-20200806_lab.xml axnx-20200806_pre.xml http://xbrl.sec.gov/dei/2019-01-31 true true JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "axnx-063020x8kdocument.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "calculationLink": { "local": [ "axnx-20200806_cal.xml" ] }, "definitionLink": { "local": [ "axnx-20200806_def.xml" ], "remote": [ "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-eedm-def-2020-01-31.xml", "http://xbrl.fasb.org/srt/2020/elts/srt-eedm1-def-2020-01-31.xml" ] }, "inline": { "local": [ "axnx-063020x8kdocument.htm" ] }, "labelLink": { "local": [ "axnx-20200806_lab.xml" ], "remote": [ "https://xbrl.sec.gov/dei/2019/dei-doc-2019-01-31.xml" ] }, "presentationLink": { "local": [ "axnx-20200806_pre.xml" ] }, "referenceLink": { "remote": [ "https://xbrl.sec.gov/dei/2019/dei-ref-2019-01-31.xml" ] }, "schema": { "local": [ "axnx-20200806.xsd" ], "remote": [ "http://xbrl.fasb.org/srt/2020/elts/srt-types-2020-01-31.xsd", "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-gaap-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-roles-2020-01-31.xsd", "http://xbrl.fasb.org/srt/2020/elts/srt-roles-2020-01-31.xsd", "https://xbrl.sec.gov/country/2020/country-2020-01-31.xsd", "http://xbrl.fasb.org/us-gaap/2020/elts/us-types-2020-01-31.xsd", "http://www.xbrl.org/lrr/arcrole/factExplanatory-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://xbrl.sec.gov/currency/2020/currency-2020-01-31.xsd", "https://xbrl.sec.gov/dei/2019/dei-2019-01-31.xsd", "https://xbrl.sec.gov/exch/2020/exch-2020-01-31.xsd", "http://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "https://xbrl.sec.gov/sic/2020/sic-2020-01-31.xsd", "https://xbrl.sec.gov/stpr/2018/stpr-2018-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 24, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2019-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 95, "memberCustom": 0, "memberStandard": 0, "nsprefix": "axnx", "nsuri": "http://axonicsmodulation.com/20200806", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "axnx-063020x8kdocument.htm", "contextRef": "D2020Q3Aug06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0001000 - Document - Cover Page", "role": "http://axonicsmodulation.com/role/CoverPage", "shortName": "Cover Page", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "div", "body", "html" ], "baseRef": "axnx-063020x8kdocument.htm", "contextRef": "D2020Q3Aug06", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-US": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-US": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-US": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-US": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-US": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-US": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2019-01-31", "presentation": [ "http://axonicsmodulation.com/role/CoverPage" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 16 0001603756-20-000070-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001603756-20-000070-xbrl.zip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end